Introduction
Skeletal muscle is an attractive tissue for non-viral gene delivery for many reasons, which include the following. Large quantities of skeletal muscle are available and accessible in animals for intramuscular injection. Muscle fibers are capable of taking up naked plasmid DNA after intramuscular adminstration. 1, 2 Exogenous plasmids in muscle cells have produced expression of transgene proteins for more than 1 year at low expression level. [1] [2] [3] Muscle can function as a 'bioreactor' to treat regional and systemic disease. 4 Finally, formulated plasmids or electroporation can lead to a large percentage of muscle cells being transfected, high level expression and excellent reproducibility. 5, 6 Transgene expression in skeletal muscle has been demonstrated using a variety of plasmid backbones and reporter genes driven by a number of viral promoters. These promoters include the cytomegalovirus (CMV) immediate-early promoter, [7] [8] [9] Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter, 1 and the SV40 early promoter. 10 However, these viral promoters may be inactivated in muscle tissue. 11 Moreover, not all of the admin-istered plasmid remains in the muscle. An uncontrolled expression of a therapeutic gene in non-target cells could potentially lead to undesirable local or systemic sideeffects. 8 An avian skeletal muscle tissue-specific ␣-actin promoter (SkA) has been employed to produce tissuespecific expression. 12 This promoter has been well-characterized and is known to be active in adult skeletal muscle tissues. 12, 13 Using this promoter, biologically active human insulin-like growth factor-I (hIGF-I) and human growth hormone (hGH) have been produced in murine muscle. 8, 9 One potential limitation of the SkA promoter to gene therapy applications is that, in general, it yields lower levels of expression in vivo than the stronger CMV viral promoter.
Barnhart et al 14 combined a number of enhancers and promoters from various muscle-specific genes with the strong CMV gene enhancer/promoter to generate a more active promoter. Only one out of the 20 combinations showed better activity than that of the CMV promoter. Nettelbeck et al 15 recently reported a strategy to enhance tissue-specific promoter activity in vitro by using the viral transactivator VP16. We have screened several non-viral muscle-specific promoter transactivators (Figure 1 ) to enhance SkA promoter transcriptional activity in muscle in vivo. In this article, we report that co-expression of a serum response factor (SRF) in murine muscle not only enhanced SkA promoter activity about 10-fold and a CMV/SkA chimeric promoter activity by five-fold, but also prolonged the duration of expression for more than 21 days. 
Results
Muscle-specific SkA promoter (pLC1072) is active in vitro but less in vivo Two expression systems with the luciferase reporter gene, one driven by muscle-specific SkA promoter (pLC1072) and the other driven by non-muscle specific CMV promoter (pLC0888), were characterized in vitro and in vivo. In chicken primary myotubes in vitro, both the muscle-specific SkA and non-specific CMV-driven systems yielded high luciferase activity (Figure 2a ), 1.7 × 10 10 and 9.9 × 10 9 rlu/mg protein, respectively. To obtain a rapid and strict comparison of the expression level for these two expression systems in vivo, samples were harvested 2 days after the plasmid injection to muscle. Differences in expression levels in vivo were observed. Lower luciferase activity was observed both in mouse tibialis cranialis and gastrocnemius muscle in vivo with the SkA-driven expression system (pLC1072), as compared with the strong viral CMV-driven system (pLC0888). Typically, the CMV-driven expression system (pLC0888) showed 200-to 500-fold higher peak luciferase activity than the SkA promoter expression system (pLC1072), 2 days after adminstration of plasmids in the tibialis muscle (Figure 2b ). This result was reproducibly observed in three independent experiments.
Co-expression of SRF activates the SkA promoter in murine muscle tissue in vivo It has been reported in vitro that SRF alone can give a two-fold enhancement of the transcriptional activity of the SkA promoter in differentiation-blocked myoblasts, 16 as well as that of the cardiac ␣-actin promoter in a fibroblastic 10T1/2 cell. 17 We have determined that coexpression of SRF with the SkA promoter stimulated the SkA promoter activity in murine muscle in vivo. The level of activation achieved by co-expression of SRF was about five-to 14-fold higher than that of SkA alone in both murine gastrocnemius and tibialis cranialis muscles on day 2 (P Ͻ 0.05) ( Figure 3 ). In three independent experiments, the average increase with SRF co-expression was about 10-fold higher than SkA alone. These results indicate that a single transcription factor, SRF, can enhance muscle-specific promoter activity in different muscle tissues in vivo.
Up-regulation of SkA promoter activity by SRF is SRFbinding dependent It is known that CArG elements, also known as muscle response elements (MRE) or serum response elements (SRE), are present in all muscle-specific promoters. These elements function as SRF binding sites and these SRF binding sites are sufficient for muscle-specific expression. 18 To evaluate if SRF binding to the SkA promoter is essential for enhancement of this promoter activity, an SRF dominant-negative mutant form (SRFpm) expression plasmid was co-administered with SkA-driven luciferase expression construct (pLC1072) in gastrocnemius muscle. This mutant has three point mutations in the DNA binding domain of SRF that converts three critical base contact amino acids, Arg143, Lys145 and Leu146, to the neutral amino acids, ILU143, ALA145 and GLY146, respectively. 19 These mutations abolish the DNA binding activity of the mutant form SRF, SRFpm. As expected, no enhancement of luciferase activity was observed when SkA-driven luciferase (pLC1072) was co-expressed with pSRFpm ( Figure 4a ). The loss of DNA binding activity of SRFpm totally abrogated augmentation of SkA activity. A truncated form of SRF (SRF1-266), in which the C-terminal activation domain was deleted and the DNA binding and dimerization domain were preserved, enhanced SkA promoter activity only moderately (Figure 4a ). These results suggest that binding of functional SRF to the promoter is critical for promoter activation.
To test further the hypothesis that SRF binding to SkA promoter is essential for enhancement of the promoter activity, we varied the ratio of SRF expression plasmid (pSRF) to the SkA-driven luciferase plasmid (pLC1072). A 10 g dose of SkA-luciferase (pLC1072) was formulated with various amounts of SRF expression plasmid (pSRF) ranging from 0.5 to 5 g. To keep the total DNA amounts administered constant (15 g) for each murine tibialis muscle, an 'empty plasmid' with no coding sequence (pCGN) was included in the formulation as needed. Luciferase activity of the murine tibialis muscle tissue was determined 2 days after injection ( Figure 4b ). As the amount of pSRF decreased, luciferase expression driven by SkA promoter also decreased. The weight ratio of SRF expression plasmid to SkA-driven expression plasmid for optimal activation was 1:4. The dose dependence of SRF for the activation of SkA promoter further supports the hypothesis that this is a truly functional SRF effect.
Duration of SRF trans-activation of SkA promoter
We examined the duration of expression by activating the SkA promoter with SRF after a single dose administration. After administration of 20 g of SkA-luciferase (pLC1072) formulated with 5 g of pSRF (or pCGN for the control) plasmid, luciferase activity was assayed at 2, 7, 14 and 28 days ( Figure 5 ). The relative up-regulation of SkA activity by SRF co-expression continued for 28 days. The maximum up-regulation was observed on day 7 and declined thereafter (Figure 5a ). These data indicate that such a marked up-regulation was a persistent effect -luciferase alone (pLC1072+pCGN, --). (b) CMV-luciferase (pLC0888, -b-) was used as a control. and that the intensity of up-regulation was time-dependent. The SRF effect declined with time after injection. This decline corresponds to the decline of SkA promoter activity in muscle.
Co-expression of SRF with a CMV/SKA chimeric promoter-driven system in muscle exceeds the expression level and duration of expression of CMVdriven expression system Although SkA promoter activity was enhanced by coexpression of SRF, the gene expression level driven by this promoter was still lower than that produced by CMV promoter-driven system (Figure 4) . To develop an expression system with CMV promoter-driven expression level but with longer duration, a CMV/SkA chimeric promoter-luciferase (pLC1193) and -SEAP were constructed (pAP1396, Figure 1 ). We then examined whether this promoter could increase the expression level in muscle and retain the up-regulation responsiveness to SRF in vivo. Both luciferase (pLC1193) and SEAP (pAP1396) reporter genes were used in this experiment. SEAP was chosen as the reporter gene to permit a timecourse study by measurement of expressed protein secreted in serum with each animal. Luciferase (pLC1193) was measured at day 2 for comparison with the previous experiment. SRF co-expression enhanced CMV/SkA chimeric promoter activity to 40% of that produced by CMV promoter on day 2 (Figure 6a ). However, the expression level of SEAP driven by CMV/SkA chimeric promoter with co-expression of SRF was as high as CMV expression system on day 7, and greater than that of CMV on days 14 and 21 ( Figure 6b ). Co-expression of SRF with a chimeric promoter not only increased expression levels, but also maintained expression levels up for at least 21 days.
CMV promoter without SRF binding sites did not respond to SRF co-expression in vivo It has been well documented that SRF binds to the serum response element (SRE) in the promoter region and thereby regulates gene expression. 16 As expected, expression levels with a CMV promoter-driven system, which does not have any SRF binding site, were not changed by co-expression with SRF (Figure 6c ). These results suggest that SRF effect is promoter contextspecific, with a requirement for a SRE in the promoter.
Discussion
It has been clearly demonstrated in previous studies that a skeletal muscle-specific SkA promoter exhibits strong specificity of gene expression in muscle in vivo. 13 However, the expression levels of SkA promoter-driven system were much lower than that of the CMV promoterdriven expression system in vivo (Figure 2b ). This observation is also true for a number of other tissue-specific promoters, such as the endothelium-specific promoter. 15 To enhance the SkA promoter activity, we used two strategies. The first is the addition of a cis-element upstream of this promoter and the second is by co-expression of a trans-activator.
We have shown that CMV/SkA chimeric promoter (pLC1093 and pAP1396) produced 10% activity of the CMV promoter-driven system in vivo 2 days after injection. When an SRF trans-activator was co-expressed in vivo, this chimeric promoter activity was stimulated further (Figure 6a ). Even on day 2-3, when the expression driven by the SkA promoter was relatively low, expression driven by the CMV/SkA chimeric promoter along with co-expression of SRF was about 40-70% of the CMV promoter-driven expression ( Figure 6 ). This combination also produced higher expression levels than those of the CMV-SEAP system at day 14 and 21. More importantly, co-expression of SRF with either SkA (pLC1072) or CMC/SkA chimeric promoter (pLC1093, pAP1396) produced longer duration of expression. Thus, a combination of cis-element improvements, as well as the application of a positive transactivator such as SRF, offers a means for increasing both levels and duration of gene expression.
SRF is known as a ubiquitous and conserved transcription factor. It is a key regulator of cellular response genes termed immediate-early genes, such as Egr-1 and Egr-2, 20 and non-muscle actin. 21 The cis elements with a CArG (CC(A/T)6GG) sequence motif mediate a rapid and transient serum inducibility of these genes. More importantly, SRF has been found to be critical in musclespecific gene expression and muscle development. [16] [17] [18] [19] [22] [23] [24] [25] [26] The SRF binding motif is found within the promoters of many, if not all, important muscle-specific genes, including actin, myosin heavy chains, myosin light chain, muscle creatine kinase, dystrophin, troponin T and SRF genes. YY1, a zinc finger transcription factor, 27 also binds to the skeletal muscle ␣-actin promoter SRE1, 16, 23 and competes with SRF for binding to these SREs. Overexpression of YY1 represses these elements, and SRF overexpression is able to reverse this repression. 28 Accordingly, expression of SRF in vivo would be expected to compete with YY1 and perhaps other negative transregulators, such as F-ACT1 16 and thus in favor of more active transcription. We do not have direct nuclear runon data to support this hypothesis, because no technique is yet available for isolating nuclei from muscle tissue. Quantitative RT-PCR data did show a five-fold increase in the copy number of steady-state insulin-like growth factor-I (IGF-I, pIG0552 driven by SkA promoter, Alila et al 8 ) mRNA driven by SkA promoter with co-expression of SRF in murine muscle (data not shown). This suggests that the likely mechanism of SRF enhancement on SkAand CMV/SkA promoter-driven gene expression is to enhance the promoter transcriptional activity.
Materials and methods
Plasmid construction and preparation Six constructs with four different promoters and two reporter genes were constructed in the Valentis's plasmid backbone, which includes 107 bp of 5ЈUTR (UT12), a 117 bp of 5Ј synthetic intron (ivs8), a kanamycin resistance gene and a PUC12 backbone. Plasmid pLC1072, pLC0888 and pLC1193 all contained a luciferase reporter gene but different promoters (Figure 1 ). Constructs pAP1396 and pAP1166 had the same backbone as pLC1193 and pLC0888, but a human placental alkaline phosphatase reporter gene was used. The promoters used in various constructs were an SkA promoter, 9, 29 a CMV enhancer/promoter and a CMV/SkA chimeric promoter. The SkA promoter (pLC1072) was obtained by performing PCR on pIG0552 9 plasmid using sense primer 5Ј- AGCCTGCAGGGGCCGCTCTAGCTAGAGTCT-3Ј and antisense primer 5Ј-AGCTCGAGCCTGTGCTGACTGCG CGTCG-3Ј. The 518-bp PCR product was cut with Sse8387 and XhoI, introduced in the primer and subcloned into the Valentis's backbone cut with the same restriction enzymes. For pLC0888, the CMV enhancer/promoter was excised from pCMV-hGH-GH 7 and subcloned into standard Valentis's plasmid. The CMV/SkA chimeric promoter construct (pLC1193) was made by subcloning the CMV enhancer element cut with Sse8387I and SnaBI into pLC1072 cut with Sse8387I and StuI. SRF, SRF mutant and truncated SRF expression plasmids, pSRF, pSRFpm and pSRF1-266, respectively, were described in a previous publication. 19 The control plasmid pCGN was made by the deletion of SRF cDNA from pSRF. All SRF-related plasmids contained a CMV promoter, HSVtk 5Ј leader, an HA epitope and a 3Ј rabbit ␤-globin intron and polyadenylation site.
All plasmids were manufactured using Qiagen Giga Endotoxic Free Prep Kit (Valencia, CA, USA). Residual salts were removed from the plasmid by dialysis against sterile water (USP, Baxter Deerfield, IL, USA) with a Millipore (Bedford, MA, USA) dialysis tube. The purity of the plasmid was confirmed by 1% agarose gel electrophoresis. DNA concentration was measured by absorption at 260 nm. The percentage of supercoiled DNA to the total DNA and the OD 260/280 ratios of these plasmid preparations were in the range of 80-90% and 1.7-1.9, respectively.
Formulation and intramuscular injection of DNA plasmid Formulations were made by mixing plasmid, sterile water and 5 m NaCl to a final concentration of 150 mm. The formulation osmolarity was measured using a Fiske One-Ten Micro-Sample Osmometer (Fiske, Norwook, MA, USA).
Animals were anesthetized by intraperitoneal administration of a mixture of ketamine (42.8 mg/ml), xylazine (8.6 mg/ml) and acepromazine (1.4 mg/ml) at a dose of 0.7-1.0 ml/kg. The tibialis and gastrocnemius muscles of anesthetized 6-8-week-old CD-1 mice (Charles River, Wilmington, MA, USA) were injected intramuscularly with 25 and 50 l of formulation containing 12.5 and 25 g DNA, respectively, using a 28. G needle. The mice were kept at 37°C until they regained consciousness. The animals were killed by CO 2 asphyxiation. Tibialis cranialis and gastrocnemius muscles were harvested, transferred into an Eppendorf tube, immediately frozen in liquid nitrogen and lyophilized overnight.
Protein extraction and luciferase activity assay Frozen lyophilized muscles were homogenized using mini bead-beater (Biospec Products, Bartlesville, OK, USA) with silica beads for 2 min. One milliliter of luciferase cell lysis buffer (Promega, Madison, WI, USA) was added to the powdered muscle and the samples were homogenized for another 3 min. The suspension was centrifuged at 1500 g for 15 min, and the supernatant was used to assay total protein and luciferase activity. Luciferase activity was assayed using a microplate luminometer (Wallac, Gaithersburg, MD, USA). One hundred microliters of luciferase substrate was automatically added to 20 l of muscle extract (previously diluted 1:2) and relative light units were recorded. The total protein was determined with the BCA protein assay kit (Pierce, Rockford, IL, USA).
Statistical analysis
Experimental data were analyzed by one-way analysis of variance with measurement of relative light units as the main effect. Means of individual treatment were compared using a Student's t test when the main effect was significant. Statistical significance was defined as a P Ͻ 0.05.
